AGN
Allergan plc
NYSE
People also watch:BIIBCELGVRXGILDREGN
247.48-1.50 (-0.60%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close248.98
Open250.00
Bid248.84 x 100
Ask248.98 x 100
52wk Range195.50 - 340.34
Day's Range247.19 - 250.29
Volume274,125
Avg Vol (3m)3,574,328
As of 9:58 AM EDT. NYSE Real Time Price. Market open.
  • Reuters3 days ago

    Investors scrap for Teva Pharmaceutical bonds

    Teva Pharmaceutical raised more than US$20bn across three currencies this week via an acquisition-driven bond that took advantage of pent-up demand for corporate paper in a yield-starved market. Investors had been making space for the well-telegraphed deal ever since Teva announced its US$40.5bn acquisition of Allergan Generics earlier in the year, while declining rates across the developed world and a lack of recent supply in the US and European markets added impetus to the transaction. In Europe, Teva issued bonds that priced up to 35bp inside its secondary curve - and those outstanding bonds, in turn, tightened by an incredible 40bp during the execution process.

  • The Wall Street Journal4 days ago

    Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin

    Amgen and Allergan on said a late-stage trial of their treatment being developed as a biosimilar to Roche’s breast cancer drug Herceptin met its primary endpoint.